Blog
RSS FeedPosted by Michael Wonder on 14 Aug 2024
Relugolix for the treatment of patients with hormone sensitive prostate cancer
14 August 2024 - NICE has published final evidence-based recommendations on the use of relugolix (Orgovyx) for the treatment of ...
Posted by Michael Wonder on 10 Aug 2024
Two new treatment options for incurable blood cancer assessed
9 August 2024 - We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, ...
Posted by Michael Wonder on 09 Aug 2024
Enzalutamide for the treatment of patients with non-metastatic prostate cancer after radical prostatectomy or radiotherapy
8 August 2024 - NICE is unable to make a recommendation about the use in the NHS of enzalutamide for the ...
Posted by Michael Wonder on 07 Aug 2024
Durvalumab in combination with chemotherapy before surgery (neo-adjuvant) then alone after surgery (adjuvant) for the treatment of adults with resectable non-small-cell lung cancer
30 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Aug 2024
First targeted treatment made available for hundreds of blood cancer patients on the NHS
1 August 2024 - A take at home tablet which could be a ‘game-changer’ for hundreds of blood cancer patients ...
Posted by Michael Wonder on 30 Jul 2024
NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer
29 July 2024 - Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE ...
Posted by Michael Wonder on 19 Jul 2024
More than 40,000 people could benefit after NICE recommends new ‘take at home’ pill for advanced prostate cancer
19 July 2024 - A new pill to treat advanced hormone sensitive prostate cancer that could benefit just over 40,000 ...
Posted by Michael Wonder on 18 Jul 2024
Rucaparib camsylate for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
8 July 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 18 Jul 2024
Teclistamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments (review of previous guidance)
16 July 2024 - The Department of Health and Social Care has asked the NICE to review the guidance on ...
Posted by Michael Wonder on 16 Jul 2024
Elranatamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments
12 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 15 Jul 2024
Clinical benefit, reimbursement outcomes, and prices of FDA approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis
11 July 2024 - Project Orbis is a global initiative that aims to streamline regulatory review processes across international regulators in ...
Posted by Michael Wonder on 10 Jul 2024
Lisocabtagene maraleucel for the treatment of adults with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
10 July 2024 - NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel (Breyanzi) ...
Posted by Michael Wonder on 04 Jul 2024
Lisocabtagene maraleucel for the treatment of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
4 July 2024 - NICE is unable to make a recommendation on the use of lisocabtagene maraleucel (Breyanzi) in the NHS ...
Posted by Michael Wonder on 03 Jul 2024
Osimertinib mesylate for the adjuvant treatment of patients with EGFR mutation positive non-small-cell lung cancer after complete tumour resection
27 June 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 12 Jun 2024
Pembrolizumab in combination with trastuzumab and chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma (final guidance)
12 June 2024 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with trastuzumab and ...